Most people infected by the SARS-CoV-2 virus which causes COVID-19 disease experience mild or no symptoms. Severe forms of the disease are often marked by a hyper-inflammatory response known as a cytokine storm. Thus, biomarker tests which can identify these patients and place them on the appropriate treatment regime at the earliest possible phase would help to improve outcomes. Here we describe an automated microarray-based immunoassay using the Fraunhofer lab-on-a-chip platform for analysis of C-reactive protein due to its role in the hyper-inflammatory response.
CITATION STYLE
Peter, H., Mattig, E., Guest, P. C., & Bier, F. F. (2022). Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease. In Methods in Molecular Biology (Vol. 2511, pp. 235–244). Humana Press Inc. https://doi.org/10.1007/978-1-0716-2395-4_17
Mendeley helps you to discover research relevant for your work.